Sensei Biotherapeutics Inc (FRA:407)
€ 0.367 0 (0%) Market Cap: 10.90 Mil Enterprise Value: -29.88 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 29/100

Sensei Biotherapeutics Inc to Discuss Prioritization of SNS-401-NG and SNS-VISTA Call Transcript

Jun 28, 2021 / 08:30PM GMT
Operator

Good day and thank you for standing by. Welcome to the Sensei Biotherapeutics Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions)

I would now like to turn the conference over to your speaker today, Lora Pike, vice president of Investor Relations and Communications. Please go ahead.

Lora Pike
Sensei Biotherapeutics - Vice President of Investor Relations and Communications

Thank you, [Jewel]. This is Lora Pike, head of Investor Relations and Communications. Welcome everyone to our conference call.

We issued a press release this afternoon announcing the prioritization of our pipeline focused on our next generation programs. On the call with me today with prepared remarks are John Celebi, our chief executive officer; Dr. Marie-Louise Fjaellskog, our chief medical officer; and Dr. Rob Pierce, our chief scientific officer. After our brief remarks, we will be joined by Erin Colgan, our SVP of Finance, and we'll be happy to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot